首页|期刊导航|临床与实验病理学杂志|错配修复蛋白缺陷性胶质瘤的临床病理及分子遗传学特征

错配修复蛋白缺陷性胶质瘤的临床病理及分子遗传学特征OA

Clinicopathological and molecular genetic characteristics of mismatch repair protein-deficient gliomas

中文摘要英文摘要

目的 探讨错配修复蛋白缺陷性(mismatch repair protein-deficient,dMMR)胶质瘤的临床病理学特征及分子遗传学特点.方法 收集20例经手术切除且病理确诊的dMMR胶质瘤的临床资料,采用免疫组化检测错配修复(mismatch repair,MMR)蛋白表达,并应用Sanger测序/下一代测序(next-generation sequencing,NGS)确认基因突变情况.结果 20例dMMR胶质瘤均位于幕上,其中2例为多发病灶;患者年龄15~77岁(>40岁者18例),包括5例复发和15例新发病例(遗传性和散发性).整合诊断:14例胶质母细胞瘤(IDH野生型,WHO 4级),4例星形细胞瘤(IDH突变型,WHO 4级),1例少突胶质细胞瘤(IDH突变及1p/19q共缺失型,WHO 3级)和1例弥漫性中线胶质瘤(H3K27改变,WHO 4级).组织学特征:16例(80%)可见多核瘤巨细胞,均为胶质母细胞瘤和星形细胞瘤;6例存在微血管增生.MMR蛋白表达:MLH1和(或)PMS2缺失9例,MSH2和(或)MSH6缺失10例,1例MSH2和MSH6部分缺失者经NGS检测证实存在MSH2突变.新发dMMR胶质瘤中,MLH1/PMS2和MSH2/MSH6蛋白缺陷的比例大致相当,而复发组以MSH2/MSH6蛋白缺陷为主.8例行NGS:微卫星高度不稳定检出率25%(2/8),高肿瘤突变负荷37.5%(3/8),TP53突变87.5%(7/8),NF1突变75%(6/8),NOTCH1突变50%(4/8).1例Lynch综合征相关少突胶质细胞瘤,携带IDH2 R172K、TP53和NF1突变.dMMR胶质瘤的中位总生存期9.5个月.结论 高级别胶质瘤出现多核瘤巨细胞、有淋巴细胞浸润、多发占位和复发者,需注意dMMR的筛查.MMR蛋白部分缺失时,需结合NGS和甲基化检测进一步验证.dMMR胶质瘤以TP53和NF1突变多见,少见EGFR扩增、PTEN突变和TERT启动子突变等遗传学改变.

Objective To analyze the clinicopathological and molecular genetic characteristics of mismatch re-pair protein-deficient(dMMR)gliomas.Methods Collect clinical data from 20 cases of dMMR glioma confirmed by pathological diagnosis and surgically resected.Mismatch repair(MMR)protein expression was evaluated by immuno-histochemistry,with genetic alterations confirmed via Sanger sequencing and next-generation sequencing(NGS).Re-sults All 20 dMMR gliomas were located supratentorially,with 2 cases presenting multiple lesions.Patient age ranged from 15 to 77 years;18 patients were over 40 years old.Cases included 5 recurrences and 15 newly diagnosed gliomas(hereditary and sporadic).Integrated diagnoses were:14 cases of glioblastoma(IDH wild type,WHO grade 4),4 cases of anaplastic astrocytoma(IDH mutant,WHO grade 4),1 case of anaplastic oligodendroglioma(IDH mu-tant with 1p/19q co-deletion,WHO grade 3),and 1 case of diffuse midline glioma(H3K27 alteration,WHO grade 4).Histological features:multinucleated tumor giant cells were observed in 16 cases(80%),all in glioblastoma and astrocytoma.Microvascular proliferation was present in 6 cases,with only 1 case exhibiting significant proliferation.MMR protein expression showed MLH1 and/or PMS2 loss in 9 cases,and MSH2 and/or MSH6 loss in 10 cases.One case with partial loss of MSH2 and MSH6 was confirmed to harbor an MSH2 mutation by NGS.Among the 8 cases sub-jected to NGS,molecular profiling revealed:microsatellite instability-high(MSI-H)in 25%(2/8),high tumor muta-tional burden(TMB-H)in 37.5%(3/8),TP53 mutations in 87.5%(7/8),NF1 mutations in 75%(6/8),and NOTCH1 mutations in 50%(4/8).Notably,the single Lynch syndrome-associated oligodendroglioma within this co-hort harbored concurrent IDH2 R172K,TP53,and NF1 mutations.The median overall survival for the dMMR glioma cohort was 9.5 months.Conclusion In high-grade gliomas,the presence of multinucleated giant cells,lymphocytic infiltration,multifocality,or recurrence should prompt dMMR evaluation.Pathologists should note partial loss of MMR proteins,and NGS and methylation profiling may be performed to further clarify the diagnosis when necessary.They commonly harbor TP53 and NF1 mutations,while genetic alterations such as EGFR amplification,PTEN muta-tions,and TERT promoter mutations are less frequently.

周婧;杨树东;陈刚;韩雪;孙爱娟;潘敏鸿

南京医科大学附属无锡人民医院、南京医科大学无锡医学中心、无锡市人民医院病理科,无锡 214023南京医科大学附属无锡人民医院、南京医科大学无锡医学中心、无锡市人民医院病理科,无锡 214023南京医科大学第一附属医院病理科,南京 210029南京医科大学第一附属医院病理科,南京 210029南京医科大学附属无锡人民医院、南京医科大学无锡医学中心、无锡市人民医院病理科,无锡 214023南京医科大学第一附属医院病理科,南京 210029

医药卫生

胶质瘤错配修复蛋白缺陷病理学免疫组织化学基因检测

gliomamismatch repair proteinpathologyimmunohistochemistrygenetic testing

《临床与实验病理学杂志》 2026 (3)

342-351,10

无锡市人民医院2025"雁阵人才"学科带头人-2025(2025-YZ-XKDTR-YSD-2025) 2025"Wild Goose Array Talents"Discipline Leader Fund of Wuxi People's Hospital(2025-YZ-XKDTR-YSD-2025)

10.13315/j.cnki.cjcep.2026.03.009

评论